Design Therapeutics Inc.

NASDAQ: DSGN · Real-Time Price · USD
5.26
0.10 (1.94%)
At close: Aug 15, 2025, 1:08 PM

Design Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
596K 537K 466K 129K
Gross Profit
-596K -537K -466K -129K
Operating Income
-62.38M -78.19M -67.59M -35.83M
Interest Income
12.79M n/a n/a n/a
Pretax Income
-49.59M -66.86M -63.31M -35.53M
Net Income
-49.59M -66.86M -63.31M -35.53M
Selling & General & Admin
18.03M 21.13M 18.98M 11.05M
Research & Development
44.35M 57.06M 48.61M 24.78M
Other Expenses
-596K -537K -466K n/a
Operating Expenses
61.79M 77.65M 67.13M 35.83M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
62.38M 78.19M 67.59M 35.83M
Income Tax Expense
n/a n/a n/a -107.56K
Shares Outstanding (Basic)
56.59M 55.98M 55.71M 45.94M
Shares Outstanding (Diluted)
56.59M 55.98M 55.71M 45.94M
EPS (Basic)
-0.88 -1.19 -1.14 -0.77
EPS (Diluted)
-0.88 -1.19 -1.14 -0.77
EBITDA
-48.99M -66.33M -62.84M -35.7M
EBIT
-49.59M -66.86M -63.31M -35.53M
Depreciation & Amortization
596K 537K 466K 129K